Background: Human papillomavirus is a pathogen that can cause genital warts and malignancies both in males and females. Material and method: The study was conducted as a descriptive, cross-sectional survey between June 20-30, 2023. A questionnaire was developed by reviewing similar studies to evaluate the sociodemographic structure, knowledge about HPV, knowledge about vaccination and attitude towards vaccination. Results: A total of 322 volunteers completed the questionnaire. Participants mostly gived true answers to the questions about human papillomavirus, while they gived falso answers to the questions about vaccination at a high rate. In addition, the overall Human papillomavirus knowledge score of vaccinated participants or participants willing to be vaccinated was significantly higher than that of unvaccinated participants and participants unwilling to be vaccinated (p<0.05). There was a significant and moderately strong relationship between Human papillomavirus vaccine knowledge level and willingness (Phi = 0.26, p = 2.94e-06), while there was a significant but low strenghth relationship between vaccination status (Phi = 0.17, p = 1.86e-03). It was determined that medical position, age, alcohol use and regular physical activity were more likely to negatively affect the Human papillomavirus knowledge levels of assistant health care workers. Vaccine unwillingness was also high in 27-40 age group. Conclusion: Human papillomavirus knowledge, medical position, number of sexual partners, social habits, view about vaccination, cost, religious and cultural values directly affect the rate of human papillomavirus vaccination and willingness to be vaccinated.

Introduction: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus (HCV) in the world. Aims: The aim of this study was to compare direct acting antivirals (DAAs) treatment of HCV for PWID and non-PWID in real life setting. Materials and methods: We performed a prospective, non-randomized, observational multi-center cohort study in 37 centers. All patients treated with DAAs therapy between April 1, 2017 to February 28, 2019 were included. In total, 2,713 patients were included in the study among which 250 were PWID and 2,463 were non-PWID. Besides patient characteristics, treatment response, follow-up and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: DAAs were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis.

Objectives: Severe disease characterized by interstitial pneumonia may develop in some cases of coronavirus disease (COVID-19). Periostin has been associated with many respiratory diseases. In this study, we aimed to investigate whether periostin could be a useful new biomarker in the follow-up and severity assessment of the disease in patients with COVID-19 pneumonia. Methods: In the study, 32 patients followed up during May–July 2020 due to COVID-19 and 24 healthy controls were included. The patients were divided into two groups, namely, mild/moderate and severe, according to the severity of the disease. Serum periostin and transforming growth factor beta (TGF-β) levels were tested using an enzyme-linked immunosorbent assay (ELISA) method using commercially available ELISA kits. Results: It was observed that the periostin level was significantly higher in both mild/moderate cases and severe cases compared to the control group at first presentation. However, TGF-β levels at first presentation were similar between the groups. Conclusions: Our study is the first study to investigate periostin levels in patients with COVID-19, and we believe that periostin can be used as a new biomarker. Keywords: COVID-19, Periostin, TGF-β, Pneumonia, New Biomarker Coronaviruses are among the main pathogens that mainly target the human respiratory system. Severe disease characterized by interstitial pneumonia develops in 10-20% of patients. Periostin has recently been shown to be an indicator of disease progression in idiopathic pulmonary fibrosis and asthma. In this study, we aimed to investigate whether periostin could be a useful new biomarker in the follow-up and severity assessment of the disease in patients with COVID-19 pneumonia. This article demonstrated that periostin is a useful new biomarker for disease follow-up and severity in patients with COVID-19 pneumonia. It is also the first study on periostin levels in patients with COVID-19

Objective: Migration can lead to a change in the demographic dynamics of host populations in terms of communicable diseases in destination countries. This is a potential public health challenge for health authorities. HBV and HCV infections can lead to the development of chronic liver diseases, cirrhosis and hepatocellular carcinoma, and HIV infection can lead to the development of serious opportunistic diseases. The aim of this study is to evaluate the seroprevalence of HBV, HCV and HIV in Syrian refugees and Turkish patients who were evaluated preoperatively in our hospital. Materials and methods: HBsAg, Anti-HBs, Anti-HBc, Anti-HCV and Anti-HIV results of Syrian refugee and Turkish patients who applied to surgical clinics between 2011-2021 were retrospectively reviewed. Results: The study is comprised of 54446 patients: Turkish patient group (n=20569) and Syrian refugee patient group (n=33877). The Syrian refugee patients had a significantly higher HBsAg seropositivity rate and a significantly lower anti-HBs seropositivity rate than the Turkish patients (p=0.002 and p<0.001, respectively). The anti-HCV and anti-HIV seropositivity rates were similar. The annual preoperative prevalance of HBsAg seropositivity in the Syrian refugee patients tended to significantly decrease gradually from year 2011 to year 2021 (p<0.001 for ≤30 and p=0.001 for >30 years old). Conclusion: As a result, although HBV seroprevalence gradually decreases and HCV and HIV seroprevalence is low; screening, information and treatment programs should be given due importance because of the serious disease potential and preventable conditions with precautions. In addition, preoperative screening of refugee patients coming for major surgery may be important for the safety of healthcare professionals.